|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2000-7-13
|
|
pubmed:abstractText |
Pretargeted radioimmunotherapy permits the administration of doses of 90Y five times higher than is possible with antibodies directly labeled with 90Yttrium (90Y). These high doses of 90Y introduced new issues for dosimetry that were not encountered in prior studies using conventional radioimmunotherapy. We have addressed these issues here and correlated dosimetry estimates with observed toxicity and tumor responses.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1084-9785
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
381-95
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10850323-Adenocarcinoma,
pubmed-meshheading:10850323-Antibodies, Monoclonal,
pubmed-meshheading:10850323-Biotin,
pubmed-meshheading:10850323-Dose-Response Relationship, Radiation,
pubmed-meshheading:10850323-Humans,
pubmed-meshheading:10850323-Indium Radioisotopes,
pubmed-meshheading:10850323-Kinetics,
pubmed-meshheading:10850323-Organometallic Compounds,
pubmed-meshheading:10850323-Phantoms, Imaging,
pubmed-meshheading:10850323-Radioimmunotherapy,
pubmed-meshheading:10850323-Radiopharmaceuticals,
pubmed-meshheading:10850323-Regression Analysis,
pubmed-meshheading:10850323-Streptavidin,
pubmed-meshheading:10850323-Tissue Distribution,
pubmed-meshheading:10850323-Yttrium Radioisotopes
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
|
|
pubmed:affiliation |
Division of Nuclear Medicine, Virginia Mason Medical Center, Seattle, WA 98111, USA. hbbreitz@aol.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
